Richmond Club IndexTSX Venture
S&P 500
Theoretical Richmond
Fund 1% MER
Berkshire Hathaway
19.74%
-7.31%
5.85%
13.96%
9.40%
Celebrating its 19th year of helping its members
outperform the market

Canntab Therapeutics Limited – Oral Does Cannabinoid

Company: Canntab Therapeutics Limited
Symbol: PILL.CNX
Length: 00:19:15
Presenter: Jeff Renwick, CEO & Richard Goldstein, CFO
Occasion: Richmond Club Lunch, Toronto

For a PDF of the Slide Presentations Click Here

Additional Information

 We have a clear vision to become a leader in oral dosage cannabis, with unique products that offer advantages to the medical community, patients, adult use consumers and governments.

• Clear and Sustainable Competitive Advantage Through Robust Intellectual Property with 13 patents pending.

• Well financed, publicly traded on the CSE (:PILL).

• We’ve created valuable licensing and joint venture deals in Canada and international markets, such as Australia and Germany.

• We’re launching our first two products under the 420 Therapeutics brand in the coming months.

• Along with our Canadian licensing partner, Emblem, we’ve received Health Canada approval for the development and clinical trials of our breakthrough Extended Release (XR) Tablets.

• Robust new product development, including the development of 420 Therapeutics, with the goal to be a leader in the wellness category.

• Established Leadership with a Track Record of Driving Value.

 

Head Office:
Canntab Therapeutics Limited
1 Adelaide St. East, Suite 801
Toronto, ON M5C 2V
Canada
Telephone: (416) 957-6303

E: mailto:Info@Canntab.ca
W: http://www.Canntab.ca

Be the first to comment

Leave a Reply

Your email address will not be published.


*